In exchange, Hengrui will receive $500m in upfront fees and will be eligible for approximately $12bn in development, ...

Q2 2025 Earnings Call Transcript August 12, 2025 Spero Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.03 ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.

PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for ...

Q2 2025 Earnings Call Transcript August 12, 2025 Theravance Biopharma, Inc. beats earnings expectations. Reported EPS is ...

PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero ...

Revenue (GAAP) for Q2 2025 was $3.1 million, missing the $6.2 million estimate but up from $2.3 million in the same period of 2024. Cost-cutting efforts led to lower research and administrative ...

A powerful wave of optimism continued to wash over global markets on Wednesday, propelling European equities higher as ...

In July 2025, Mersana made a payment of approximately $17.9 million to satisfy in full its indebtedness and obligations under the company’s previous loan and security agreement. The company continues ...

Theravance Biopharma's Q2 2025 earnings show robust growth with YUPELRI sales up 22%, a $225M TRELEGY royalty sale, and progress in the pivotal CYPRESS trial.